By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
King Pharmaceuticals Inc. et al. v. Intelliject Inc.
1:11-cv-00065; filed January 19, 2011 in the District Court of Delaware
• Plaintiffs: King Pharmaceuticals Inc.; Meridian Medical Technologies Inc.
• Defendant: Intelliject Inc.
Infringement of U.S. Patent No. 7,794,432 ("Automatic Injector with Kickback Attenuation," issued September 14, 2010) following a Paragraph IV certification as part of Intelliject's filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Meridian's EpiPen® Auto-Injector (epinephrine, used to treat anaphylaxis). View the complaint here.
Genetic Technologies Ltd. v. American Esoteric Laboratories et al.
1:11-cv-00057; filed January 19, 2011 in the Western District of Texas
• Plaintiff: Genetic Technologies Ltd.
• Defendants: American Esoteric Laboratories; Clinical Pathology Laboratories, Inc.; Clinical Pathology Laboratories Southeast; East Side Clinical Laboratory; Fairfax Medical Laboratories, Inc.; Clinical Pathology Laboratories Mid-Atlantic; Pathology Laboratories, Inc.; Sonic Healthcare USA, Inc.
Infringement of U.S. Patent No. 5,612,179 ("Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes," issued March 18, 1997) based on defendants' manufacture and sale or offering of genetic testing services. View the complaint here.
Prometheus Laboratories Inc. v. Roxane Laboratories, Inc.
2:11-cv-00230; filed January 14, 2011 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,284,770 ("Medicaments for the Treatment of Non-Constipated Female Irritable Bowel Syndrome," issued September 4, 2001) following a Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of Prometheus' Lotronex® (alosetron hydrochloride, used to treat women with severe diarrhea-predominant irritable bowel syndrome). View the complaint here.
Takeda Pharmaceutical Company Ltd. et al. v. Cadila Healthcare Ltd. et al.
1:11-cv-00315; filed January 14, 2011 in the Southern District of New York
• Plaintiffs: Takeda Pharmaceutical Company Ltd.; Takeda Pharmaceuticals North America, Inc.
• Defendants: Cadila Healthcare Ltd.; Zydus Pharmaceuticals USA, Inc.
Infringement of U.S. Patent Nos. 5,965,584 ("Pharmaceutical Composition," issued October 12, 1999), 6,329,404 (same title, issued December 11, 2001), 6,166,043 (same title, issued December 26, 2000), 6,172,090 (same title, issued January 9, 2001), 6,211,205 (same title, issued April 3, 2001), 6,271,243 (same title, issued August 7, 2001), and 6,303,640 (same title, issued October 16, 2001) following a Paragraph IV certification as part of Cadila's filing of an ANDA to manufacture a generic version of Takeda's Actos® (pioglitazone hydrochloride, used to treat type II diabetes). View the complaint here.
Comments